{"disease":{"id":"focal-seizure","name":"focal seizure"},"drugs":{"marketed":[{"drug_id":"xcopri","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xcopri","company_name":"SK Life Science, Inc.","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"cenobamate","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xcopri","generic_name":"CENOBAMATE","company_name":"Sk Life","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Xcopri works by enhancing the activity of a neurotransmitter called GABA, which helps calm down abnormal electrical activity in the brain."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07287163","title":"Clinical Trial of Vormatrigine in Adult Patients With Epilepsy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":700,"lead_sponsor_name":"Praxis Precision Medicines","has_results":false},{"nct_id":"NCT03373383","title":"Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT03370120","title":"Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":406,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT05614063","title":"A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"Xenon Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT05747001","title":"This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK","phase":"","overall_status":"COMPLETED","enrollment_count":319,"lead_sponsor_name":"Aziende Chimiche Riunite Angelini Francesco S.p.A","has_results":false},{"nct_id":"NCT03739840","title":"A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":232,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06999902","title":"Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"Praxis Precision Medicines","has_results":false},{"nct_id":"NCT04737837","title":"A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT06922175","title":"REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Aziende Chimiche Riunite Angelini Francesco S.p.A","has_results":false},{"nct_id":"NCT04770337","title":"Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Neuroelectrics Corporation","has_results":false},{"nct_id":"NCT04836559","title":"A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT05159908","title":"A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Neurocrine Biosciences","has_results":false},{"nct_id":"NCT07141329","title":"SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07233239","title":"A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT05493293","title":"Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Neurocrine Biosciences","has_results":false},{"nct_id":"NCT03457961","title":"Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06899230","title":"Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"iQure Australia Pty Ltd","has_results":false},{"nct_id":"NCT03283371","title":"Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06453213","title":"Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"SK Life Science, Inc.","has_results":false},{"nct_id":"NCT07219407","title":"A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Rapport Therapeutics Inc.","has_results":false},{"nct_id":"NCT06377930","title":"Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Rapport Therapeutics Inc.","has_results":false},{"nct_id":"NCT05473442","title":"Study of EQU-001 for Uncontrolled Focal Onset Seizures","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Equilibre Biopharmaceuticals B.V.","has_results":false},{"nct_id":"NCT03474770","title":"BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06388707","title":"A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":8,"lead_sponsor_name":"NaviFUS Corporation","has_results":false},{"nct_id":"NCT05605756","title":"BOTOX Effects on Seizure Severity and Susceptibility","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT05738226","title":"EpiCare@Home Validation Study for Focal Onset Seizures","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Byteflies","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}